Cargando…

All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study

BACKGROUND: Chronic liver disease (CLD) is a growing cause of morbidity and mortality worldwide, particularly in low to middle-income countries with high disease burden and limited treatment availability. Coffee consumption has been linked with lower rates of CLD, but little is known about the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Oliver J., Fallowfield, Jonathan A., Poole, Robin, Hayes, Peter C., Parkes, Julie, Roderick, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218514/
https://www.ncbi.nlm.nih.gov/pubmed/34154561
http://dx.doi.org/10.1186/s12889-021-10991-7
_version_ 1783710781854973952
author Kennedy, Oliver J.
Fallowfield, Jonathan A.
Poole, Robin
Hayes, Peter C.
Parkes, Julie
Roderick, Paul J.
author_facet Kennedy, Oliver J.
Fallowfield, Jonathan A.
Poole, Robin
Hayes, Peter C.
Parkes, Julie
Roderick, Paul J.
author_sort Kennedy, Oliver J.
collection PubMed
description BACKGROUND: Chronic liver disease (CLD) is a growing cause of morbidity and mortality worldwide, particularly in low to middle-income countries with high disease burden and limited treatment availability. Coffee consumption has been linked with lower rates of CLD, but little is known about the effects of different coffee types, which vary in chemical composition. This study aimed to investigate associations of coffee consumption, including decaffeinated, instant and ground coffee, with chronic liver disease outcomes. METHODS: A total of 494,585 UK Biobank participants with known coffee consumption and electronic linkage to hospital, death and cancer records were included in this study. Cox regression was used to estimate hazard ratios (HR) of incident CLD, incident CLD or steatosis, incident hepatocellular carcinoma (HCC) and death from CLD according to coffee consumption of any type as well as for decaffeinated, instant and ground coffee individually. RESULTS: Among 384,818 coffee drinkers and 109,767 non-coffee drinkers, there were 3600 cases of CLD, 5439 cases of CLD or steatosis, 184 cases of HCC and 301 deaths from CLD during a median follow-up of 10.7 years. Compared to non-coffee drinkers, coffee drinkers had lower adjusted HRs of CLD (HR 0.79, 95% CI 0.72–0.86), CLD or steatosis (HR 0.80, 95% CI 0.75–0.86), death from CLD (HR 0.51, 95% CI 0.39–0.67) and HCC (HR 0.80, 95% CI 0.54–1.19). The associations for decaffeinated, instant and ground coffee individually were similar to all types combined. CONCLUSION: The finding that all types of coffee are protective against CLD is significant given the increasing incidence of CLD worldwide and the potential of coffee as an intervention to prevent CLD onset or progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-10991-7.
format Online
Article
Text
id pubmed-8218514
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82185142021-06-23 All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study Kennedy, Oliver J. Fallowfield, Jonathan A. Poole, Robin Hayes, Peter C. Parkes, Julie Roderick, Paul J. BMC Public Health Research Article BACKGROUND: Chronic liver disease (CLD) is a growing cause of morbidity and mortality worldwide, particularly in low to middle-income countries with high disease burden and limited treatment availability. Coffee consumption has been linked with lower rates of CLD, but little is known about the effects of different coffee types, which vary in chemical composition. This study aimed to investigate associations of coffee consumption, including decaffeinated, instant and ground coffee, with chronic liver disease outcomes. METHODS: A total of 494,585 UK Biobank participants with known coffee consumption and electronic linkage to hospital, death and cancer records were included in this study. Cox regression was used to estimate hazard ratios (HR) of incident CLD, incident CLD or steatosis, incident hepatocellular carcinoma (HCC) and death from CLD according to coffee consumption of any type as well as for decaffeinated, instant and ground coffee individually. RESULTS: Among 384,818 coffee drinkers and 109,767 non-coffee drinkers, there were 3600 cases of CLD, 5439 cases of CLD or steatosis, 184 cases of HCC and 301 deaths from CLD during a median follow-up of 10.7 years. Compared to non-coffee drinkers, coffee drinkers had lower adjusted HRs of CLD (HR 0.79, 95% CI 0.72–0.86), CLD or steatosis (HR 0.80, 95% CI 0.75–0.86), death from CLD (HR 0.51, 95% CI 0.39–0.67) and HCC (HR 0.80, 95% CI 0.54–1.19). The associations for decaffeinated, instant and ground coffee individually were similar to all types combined. CONCLUSION: The finding that all types of coffee are protective against CLD is significant given the increasing incidence of CLD worldwide and the potential of coffee as an intervention to prevent CLD onset or progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-10991-7. BioMed Central 2021-06-22 /pmc/articles/PMC8218514/ /pubmed/34154561 http://dx.doi.org/10.1186/s12889-021-10991-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kennedy, Oliver J.
Fallowfield, Jonathan A.
Poole, Robin
Hayes, Peter C.
Parkes, Julie
Roderick, Paul J.
All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study
title All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study
title_full All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study
title_fullStr All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study
title_full_unstemmed All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study
title_short All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study
title_sort all coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a uk biobank study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218514/
https://www.ncbi.nlm.nih.gov/pubmed/34154561
http://dx.doi.org/10.1186/s12889-021-10991-7
work_keys_str_mv AT kennedyoliverj allcoffeetypesdecreasetheriskofadverseclinicaloutcomesinchronicliverdiseaseaukbiobankstudy
AT fallowfieldjonathana allcoffeetypesdecreasetheriskofadverseclinicaloutcomesinchronicliverdiseaseaukbiobankstudy
AT poolerobin allcoffeetypesdecreasetheriskofadverseclinicaloutcomesinchronicliverdiseaseaukbiobankstudy
AT hayespeterc allcoffeetypesdecreasetheriskofadverseclinicaloutcomesinchronicliverdiseaseaukbiobankstudy
AT parkesjulie allcoffeetypesdecreasetheriskofadverseclinicaloutcomesinchronicliverdiseaseaukbiobankstudy
AT roderickpaulj allcoffeetypesdecreasetheriskofadverseclinicaloutcomesinchronicliverdiseaseaukbiobankstudy